FRONTEO Inc. (Headquarters: Minato-ku, Tokyo, President: Masahiro Morimoto, hereinafter FRONTEO) uses the uniquely developed AI system "Cascade Eye" to visualize the mechanism of diseases and drugs, and uses the new coronavirus. We are pleased to announce that we will start research on drug repositioning for infectious diseases (COVID-19).

　"Cascade Eye" analyzes information on molecules and genes related to various diseases in a short time through artificial intelligence, and analyzes this information on a pathway map.^■1It is a system that can be visualized in the form.Our natural language analysis AI engine "Concept Encoder (concept encoder)^®, Concept Encoder) ”, PubMed^■2And Open Targets^■3From the latest database existing in, we can instantly find papers and pharmaceutical research data to be referred to, and express their relevance and mechanism in a pathway.Since AI makes decisions without human assumptions or biases, it can be applied not only to discover new targets and biomarkers that cannot be considered with existing knowledge, but also to predict efficacy and safety, and is custom-made therapy and personalization. We are also considering the use of treatments such as domedicon for individualization.

　In this research, we will use "Cascade Eye" to construct a pathway map of the new coronavirus infection (COVID-19) to visually capture important molecules, genes, drug candidates, etc. related to the infection. I will.Based on this visualized information, we aim to discover therapeutic possibilities with existing drugs, new targets, and concomitant drug candidates to effectively block multiple paths. FRONTEO believes that the results of this research will lead to prevention of aggravation and early recovery.

　The pathway map for the new coronavirus infection (COVID-19) created as a result of this research will be announced again in the form of a press release so that it can be used in various places concerned.

Papers and medical data analyzed by Cascade Eye are converted into location information and plotted in a spherical shape (left).
Furthermore, the relationships and developmental order of genes and molecules are expressed in the pathway map = pathway map (right).

* 1 A pathway diagram showing the interaction of genes and molecules
* 2 PubMed: A database that allows you to search for biological and medical treatises. Located in the NLM (National Library of Medicine)
Created by NCBI (National Center for Biotechnology Information).
* 3 Open Targets: Database for drug discovery target discovery through public-private partnership

■ Concept Encoderabout　URL: https://lifescience.fronteo.com/

"Concept Encoder (concept encoder)^®, Concept Encoder) ”is a natural language analysis AI (artificial intelligence) developed by FRONTEO specializing in the life science field.It was developed in 2018 with the aim of effectively analyzing and utilizing medical data containing a large amount of free-form text data based on evidence. "Concept Encoder" can be co-analyzed with data other than text, and we are conducting research on co-analysis with numerical data such as gene expression information, vitals and various test values ​​accumulated in the life science field.Patent registration number: Patent No. 6346367

■ FRONTEOabout　URL: https://www.fronteo.com/

FRONTEO Inc. has developed its own natural language analysis AI (artificial intelligence) engine "KIBIT".^®(Kibit) ”and“ concept encoder^®(Concept encoder) ”is a company that supports information analysis.Established in August 2003 as a company that supports e-discovery (electronic discovery), which preserves evidence, investigates and analyzes electronic data necessary for international proceedings, and digital forensic investigations, and technologies such as an in-house developed data analysis platform To date, we have supported about 8 international proceedings.In addition, we are applying the unique AI-related technology cultivated in the legal business to areas such as life science and business intelligence, and have achieved results in drug discovery research support, diagnostic support, and work style reform. Listed on TSE Mothers on June 1, 2007.The capital is 6 thousand yen (as of March 26, 2,559,206).